# CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

> **NCT07181720** · PHASE1 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 90 (estimated)

## Conditions studied

- Renal Cell Carcinoma (RCC)
- Lung Cancer
- Anaplastic Thyroid Carcinomas
- Ovarian Cancer
- Cervical Cancer
- Thymic Carcinoma

## Interventions

- **BIOLOGICAL:** CD70-targeted CAR-T cells
- **BIOLOGICAL:** CD70-targeted CAR-T cells
- **BIOLOGICAL:** CD70-targeted CAR-T cells

## Key facts

- **NCT ID:** NCT07181720
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-12
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07181720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07181720, "CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07181720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*